Interventional device developer Boston Scientific of Natick, MA, has submitted the fifth and final module of its premarket application (PMA) to the U.S. Food and Drug Administration for its Taxus Express 2 paclitaxel-eluting coronary stent system. Submission of the final module starts the official regulatory review process of the PMA at the FDA.
By AuntMinnie.com staff writersJune 19, 2003
Related Reading
Boston Scientific inks deal for device-tracking technology, May 19, 2003
Boston Scientific names Patel as VP, May 15, 2003
Boston Scientific starts Taxus V clinical trials, March 18, 2003
FDA grants Boston Scientific stent expedited status, March 13, 2003
Boston Scientific submits stent for PMA, February 25, 2003
Copyright © 2003 AuntMinnie.com
